

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

On 29 March 2001  
TOWNSEND and TOWNSEND and CREW LLP  
By: Malinda Wogot

PATENT  
Attorney Docket No.: 18623-013910US  
Client Reference No.: EPI 0139.10 US

TECH CENTER 1600/2820

APR 04 2001

RECEIVED

# 81A  
KD  
4-20-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re application of:*

Sette *et al.*

Application No.: 09/350,401

Filed: July 8, 1999

For: INDUCING CELLULAR IMMUNE  
RESPONSES TO HEPATITIS B VIRUS  
USING PEPTIDE AND NUCLEIC ACID  
COMPOSITIONS

Examiner Ronald B. Schwadron, Ph.D.

Art Unit: 1644

AMENDMENT AND COMMUNICATION  
UNDER 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 29, 2000, Applicants respectfully request entry of the following amendment and sequence listing. Submitted herewith is the required paper copy and computer readable copy of the Sequence Listing. A fee transmittal for five months extension of time for response from October 29, 2000 to March 29, 2001 is filed herewith.

Please insert the Sequence Listing pages 1-830 in the application after the claims.

Please amend the application as follows: